Celecoxib Export Market Intelligence: India's 326 Suppliers Shipping to 112 Countries — TransData Nexus 2026

Q: Who are the top celecoxib exporters from India?

The top celecoxib exporters from India are: 1. UMEDICA LABORATORIES PRIVATE LIMITED — $24.8M (18.6% market share); 2. MACLEODS PHARMACEUTICALS LTD — $18.6M (13.9% market share); 3. ALEMBIC PHARMACEUTICALS LIMITED — $12.2M (9.1% market share); 4. CIPLA LIMITED — $12.2M (9.1% market share); 5. MICRO LABS LIMITED — $6.8M (5.1% market share). Together they account for 55.8% of India's total celecoxib export value.

Q: What is the total export value of celecoxib from India?

The total export value of celecoxib from India is $133.6M USD, recorded across 4,880 shipment transactions from 326 active exporters to 112 destination countries. The average shipment value is $27.4K.

Q: Which countries import celecoxib from India?

India exports celecoxib to 112 countries worldwide. The top importing countries are: UNITED STATES (49.9% share, $66.7M), PHILIPPINES (10.2% share, $13.7M), CANADA (5.3% share, $7.1M), FRANCE (2.6% share, $3.4M), GERMANY (2.3% share, $3.1M). These five markets account for 70.3% of total export value.

Q: What is the HS code for celecoxib exports from India?

The primary HS code for celecoxib exports from India is 30049069. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of celecoxib exports from India?

The average unit price for celecoxib exports from India is $4.39 USD per unit, with prices ranging from $0.00 to $730.67 depending on formulation, packaging, and order volume. The total market is valued at $133.6M across 4,880 shipments.

Q: Which ports handle celecoxib exports from India?

The primary ports for celecoxib exports from India are NHAVA SHEVA SEA (INNSA1) (11.1% of shipments), DELHI AIR CARGO ACC (INDEL4) (9.7% of shipments), SAHAR AIR CARGO ACC (INBOM4) (8.9% of shipments), SAHAR AIR (6.6% of shipments), JNPT/ NHAVA SHEVA SEA (6.3% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of celecoxib?

India is one of the world's leading exporters of celecoxib due to its large base of 326 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports celecoxib to 112 countries, demonstrating 57% global market coverage.

Q: What certifications do Indian celecoxib exporters need?

Indian celecoxib exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import celecoxib from India?

There are 781 registered buyers importing celecoxib from India, spread across 112 countries. The repeat buyer rate is 61.6%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top celecoxib supplier from India?

UMEDICA LABORATORIES PRIVATE LIMITED is the leading celecoxib exporter from India with a market share of 18.6% and total export value of $24.8M across 65 shipments. The top 5 suppliers together control 55.8% of total export value.

Suresh Sormare

Celecoxib

India Pharmaceutical Trade Intelligence

$133.6M326 Suppliers112 CountriesHS 30049069

ExportsIndia → UNITED STATES49.9%India → PHILIPPINES10.2%

ImportsGERMANY → India$50.3M FRANCE → India$57.8K

#1 Supplier: UMEDICA LABORATORIES #1 Buyer: LIFESCIENCE LOGISTICS

Celecoxib Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Celecoxib to the World

Between 2022 and 2026, India exported $133.6M worth of celecoxib across 4,880 verified shipments to 112 countries — covering 57% of world markets in the Analgesics & Antipyretics segment. The largest destination is UNITED STATES (49.9%). UMEDICA LABORATORIES PRIVATE LIMITED leads with a 18.6% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Celecoxib export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Celecoxib export data snapshot — $133.6M · 326 exporters · 112 countriesTransData Nexus · Indian Customs Data

Top Celecoxib Exporters from India

326 active exporters · Ranked by export value

View all 326 →

Top Celecoxib Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	UMEDICA LABORATORIES PRIVATE LIMITED	$24.8M	65	2	18.6%
2	MACLEODS PHARMACEUTICALS LTD

Top Countries Importing Celecoxib from India

112 destination markets · Ranked by import value

All 112 countries →

Top Countries Importing Celecoxib from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	UNITED STATES	$66.7M	49.9%
2	PHILIPPINES	$13.7M	10.2%
3	CANADA	$7.1M	5.3%
4	FRANCE	$3.4M	2.6%
5	GERMANY	$3.1M	2.3%
6	MALAYSIA	$3.0M	2.3%
7	AUSTRALIA	$2.8M	2.1%
8	CHILE	$2.8M	2.1%
9	SRI LANKA	$2.7M	2.1%
10	MAURITIUS	$2.2M	1.6%

UNITED STATES is India's largest celecoxib export destination, absorbing 49.9% of total exports worth $66.7M. The top 5 importing countries — UNITED STATES, PHILIPPINES, CANADA, FRANCE, GERMANY — together account for 70.3% of India's total celecoxib export value. The remaining 107 destination countries collectively receive the other 29.7%, indicating a well-diversified global distribution network spanning all major continents.

Who Supplies Celecoxib to India?

14 origin countries · Total import value: $50.4M

India imports celecoxib from 14 countries with a combined import value of $50.4M. The largest supplier is GERMANY ($50.3M, 38 shipments), followed by FRANCE and BELGIUM. All values are from Indian Customs (DGFT) import records.

Countries Supplying Celecoxib to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	GERMANY	$50.3M	38	99.8%
2	FRANCE	$57.8K	2	0.1%
3	BELGIUM	$41.4K	1	0.1%
4	UNITED STATES	$17.9K	6	0.0%
5	JAPAN	$978	2	0.0%
6	SWITZERLAND	$951	1	0.0%
7	IRELAND	$399	1	0.0%
8	SPAIN	$281	3	0.0%
9	BRAZIL	$242	1	0.0%
10	BULGARIA	$216	1	0.0%

Showing top 10 of 14 origin countries

GERMANY is the largest supplier of celecoxib to India, accounting for 99.8% of total import value. The top 5 origin countries — GERMANY, FRANCE, BELGIUM, UNITED STATES, JAPAN — together supply 100.0% of India's celecoxib imports. Click any country to see detailed supplier and buyer data for that import corridor.

Celecoxib — Export Intelligence Video

Visual overview of India's celecoxib import and export market — top suppliers, destinations, pricing, and trade routes

This video covers India's celecoxib pharmaceutical import and export market — $133.6M in total trade, 326 verified manufacturers, and 112 destination countries. Data sourced from Indian Customs (DGFT) shipment records.

Regulatory Landscape — Celecoxib

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, celecoxib is approved for the treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The original New Drug Application (NDA) for Celebrex (celecoxib) was approved by the FDA on December 23, 1998. Subsequently, numerous Abbreviated New Drug Applications (ANDAs) have been approved, allowing for the marketing of generic versions. The FDA's Orange Book lists multiple approved ANDAs for celecoxib, indicating a competitive generic market. Notably, the high number of Indian exporters (326) underscores India's pivotal role in supplying generic celecoxib to the U.S. market.

Regarding import alerts, as of March 2026, there are no active FDA import alerts specifically targeting celecoxib products from India. However, manufacturers must adhere to the FDA's stringent Current Good Manufacturing Practice (CGMP) regulations to ensure product quality and safety. The regulatory pathway for generic celecoxib involves demonstrating bioequivalence to the reference listed drug, compliance with CGMP, and submission of an ANDA for FDA review and approval.

2EU & UK Regulatory Framework

In the European Union, celecoxib is authorized for the symptomatic treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The European Medicines Agency (EMA) granted marketing authorization for Onsenal (celecoxib) on October 17, 2003, specifically for the reduction of adenomatous intestinal polyps in familial adenomatous polyposis (FAP). However, this authorization was withdrawn on March 28, 2011, due to insufficient data confirming clinical benefit. The EMA concluded that the benefit of celecoxib in FAP patients had not been sufficiently demonstrated and did not outweigh the increased risk of cardiovascular and gastrointestinal side effects. (ema.europa.eu)

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the regulation of medicinal products. Following Brexit, the UK has established its own regulatory framework, though it closely aligns with EMA guidelines. Manufacturers exporting to the UK must comply with the MHRA's requirements, including obtaining marketing authorization and adhering to Good Manufacturing Practice (GMP) standards.

3WHO Essential Medicines & Global Standards

Celecoxib is included in the World Health Organization's (WHO) Model List of Essential Medicines, recognizing its importance in a basic health system. The WHO Model List serves as a guide for the development of national and institutional essential medicine lists. Regarding pharmacopoeial standards, celecoxib is monographed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). These monographs provide standardized specifications for the quality, purity, and strength of the drug, ensuring consistency across different markets.

4India Regulatory Classification

In India, celecoxib is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), regulates the pricing of essential medicines. As of March 2026, celecoxib is not listed under the DPCO's price control list, allowing manufacturers to set prices based on market dynamics. For exports, the Directorate General of Foreign Trade (DGFT) mandates that pharmaceutical products, including celecoxib, obtain a No Objection Certificate (NOC) to ensure compliance with export regulations and to prevent shortages in the domestic market.

5Patent & Exclusivity Status

The primary patents for celecoxib have expired, leading to a robust generic market with multiple manufacturers producing the drug. This expiration has facilitated increased competition, resulting in more affordable pricing and wider accessibility. The presence of 326 active Indian exporters highlights the competitive landscape and India's significant contribution to the global supply of generic celecoxib.

6Recent Industry Developments

In June 2025, the FDA approved a new generic version of celecoxib, further intensifying market competition and potentially impacting pricing strategies for existing manufacturers.

In September 2025, the EMA updated its guidelines on the cardiovascular safety of NSAIDs, including celecoxib, emphasizing the need for ongoing pharmacovigilance and risk assessment.

In December 2025, the NPPA conducted a review of non-scheduled drug prices, including celecoxib, to monitor market trends and ensure fair pricing practices.

In February 2026, the WHO released a report highlighting the importance of maintaining quality standards in the manufacturing of essential medicines like celecoxib, urging member countries to strengthen regulatory oversight.

In March 2026, the DGFT introduced a streamlined process for obtaining export NOCs for pharmaceutical products, aiming to facilitate smoother export operations for manufacturers.

These developments underscore the dynamic nature of the pharmaceutical industry and the importance of staying abreast of regulatory changes to ensure compliance and market competitiveness.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Celecoxib

Retail & reference prices across 9 markets vs. India FOB export price of $4.39/unit

Global Price Benchmark for Celecoxib across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$0.13	USD	According to the FDA Orange Book, generic versions of Celecoxib are available, contributing to competitive pricing in the U.S. market.
United Kingdom	$0.39	GBP	The NHS Drug Tariff lists Celecoxib, ensuring regulated pricing within the National Health Service framework.
Germany	$0.38	EUR	The Federal Institute for Drugs and Medical Devices (BfArM) regulates pharmaceutical pricing, maintaining affordability for patients.
Australia	$0.34

Supply Chain Risk Assessment — Celecoxib

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

India's pharmaceutical industry, including the production of Celecoxib, heavily relies on Key Starting Materials (KSMs) sourced from China. This dependency is significant, as China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply. Such reliance exposes the supply chain to vulnerabilities stemming from geopolitical tensions, trade disputes, and environmental regulations affecting Chinese manufacturing.

Recent disruptions have underscored these risks. In September 2025, China implemented aggressive pricing strategies, slashing the prices of 41 APIs and KSMs by 40–50%, aiming to undercut Indian manufacturers. Additionally, in February 2025, the FDA issued warning letters to API manufacturers in China and India for significant deviations from current Good Manufacturing Practices (cGMP), highlighting ongoing quality concerns. These events have led to supply chain disruptions and increased costs for Indian pharmaceutical companies.

2Supplier Concentration & Single-Source Risk

The export market for Celecoxib from India is notably concentrated. The top five exporters—UMEDICA LABORATORIES PRIVATE LIMITED, MACLEODS PHARMACEUTICALS LTD, ALEMBIC PHARMACEUTICALS LIMITED, CIPLA LIMITED, and MICRO LABS LIMITED—account for 55.8% of total exports, with UMEDICA alone holding an 18.6% share. This concentration poses a risk, as disruptions affecting these key suppliers could significantly impact global supply.

Access Complete Celecoxib Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 4,880 transactions across 112 markets.

Request Demo View Pricing

Frequently Asked Questions — Celecoxib Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top celecoxib exporters from India?

The leading celecoxib exporters from India are UMEDICA LABORATORIES PRIVATE LIMITED, MACLEODS PHARMACEUTICALS LTD, ALEMBIC PHARMACEUTICALS LIMITED, and 12 others. UMEDICA LABORATORIES PRIVATE LIMITED leads with 18.6% market share ($24.8M). The top 5 suppliers together control 55.8% of total export value.

What is the total export value of celecoxib from India?

The total export value of celecoxib from India is $133.6M, recorded across 4,880 shipments from 326 active exporters to 112 countries. The average shipment value is $27.4K.

Which countries import celecoxib from India?

India exports celecoxib to 112 countries. The top importing countries are UNITED STATES (49.9%), PHILIPPINES (10.2%), CANADA (5.3%), FRANCE (2.6%), GERMANY (2.3%), which together account for 70.3% of total export value.

What is the HS code for celecoxib exports from India?

The primary HS code for celecoxib exports from India is 30049069. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Celecoxib

Celecoxib

Top Celecoxib Exporters from India

Top Countries Importing Celecoxib from India

Who Supplies Celecoxib to India?

Quick Facts

Related Analgesics & Antipyretics

Related Analysis

Need Details?

Celecoxib — Export Intelligence Video

Regulatory Landscape — Celecoxib

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Celecoxib

Supply Chain Risk Assessment — Celecoxib

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Celecoxib Trade Intelligence

Frequently Asked Questions — Celecoxib Exports from India

Who are the top celecoxib exporters from India?

What is the total export value of celecoxib from India?

Which countries import celecoxib from India?

What is the HS code for celecoxib exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of celecoxib exports from India?

Which ports handle celecoxib exports from India?

Why is India a leading exporter of celecoxib?

What certifications do Indian celecoxib exporters need?

How many buyers import celecoxib from India?

What is the market share of the top celecoxib exporter from India?

Analysis Methodology